A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations

•Erlotinib 100 mg daily and binimetinib 15 mg BID × 5 days/week was well tolerated.•Common toxicities observed included grade 1–2 diarrhea, rash, fatigue, and nausea.•PK revealed no significant drug-drug interaction between binimetinib and erlotinib.•Modest clinical activity was seen in KRAS-mutant patients including 1 confirmed PR.•No responses were seen among EGFR-mutant patients with progression on prior TKI.